CoChat

Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information

Open access
Hamamoto, Ryuji, Koyama, Takafumi, Kouno, Nobuji, Yasuda, Tomohiro, Yui, Shuntaro, Sudo, Kazuki, Hirata, Makoto, Sunami, Kuniko, Kubo, Takashi, Takasawa, Ken, Takahashi, Satoshi, Machino, Hidenori, Kobayashi, Kazuma, Asada, Ken, Komatsu, Masaaki, Kaneko, Syuzo, Yatabe, Yasushi, Yamamoto, Noboru · 2022 · Experimental Hematology & Oncology
Cited by 48

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Since U.S. President Barack Obama announced the Precision Medicine Initiative in his New Year’s State of the Union address in 2015, the establishment of a precision medicine system has been emphasized worldwide, particularly in the field of oncology. With the advent of next-generation sequencers specifically, genome analysis technology has made remarkable progress, and there are active efforts to apply genome information to diagnosis and treatment. Generally, in the process of feeding back the results of next-generation sequencing analysis to patients, a molecular tumor board (MTB), consisting of experts in clinical oncology, genetic medicine, etc., is established to discuss the results. On the other hand, an MTB currently involves a large amount of work, with humans searching through vast databases and literature, selecting the best drug candidates, and manually confirming the status of available clinical trials. In addition, as personalized medicine advances, the burden on MTB members is expected to increase in the future. Under these circumstances, introducing cutting-edge artificial intelligence (AI) technology and information and communication technology to MTBs while reducing the burden on MTB members and building a platform that enables more accurate and personalized medical care would be of great benefit to patients. In this review, we introduced the latest status of elemental technologies that have potential for AI utilization in MTB, and discussed issues that may arise in the future as we progress with AI implementation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40164-022-00333-7

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 48

Metadata

Authors
Hamamoto, R., Koyama, T., Kouno, N., Yasuda, T., Yui, S., Sudo, K., Hirata, M., Sunami, K., Kubo, T., Takasawa, K., Takahashi, S., Machino, H., Kobayashi, K., Asada, K., Komatsu, M., Kaneko, S., Yatabe, Y., & Yamamoto, N.
Venue
Experimental Hematology & Oncology
Published
2022-10-31
Volume
11
Issue
1
Pages
82-82
ISSN
2162-3619 (ISSN-L)
OpenAlex
W4307887190
Cited by
48
References
29
FWCI
2.02
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information. https://app.cochat.ai/papers/10.1186/s40164-022-00333-7
The paper
Hamamoto, R., Koyama, T., Kouno, N., Yasuda, T., Yui, S., Sudo, K., Hirata, M., Sunami, K., Kubo, T., Takasawa, K., Takahashi, S., Machino, H., Kobayashi, K., Asada, K., Komatsu, M., Kaneko, S., Yatabe, Y., & Yamamoto, N. (2022). Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information. Experimental Hematology & Oncology. https://doi.org/10.1186/s40164-022-00333-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.